EUVIMEDObjevte EUVIMED
Systematische ÜbersichtNetzwerk-MetaanalyseOpen access · CC BY 4.0

Biological Therapy and Small Molecules for Adults With Crohn's Disease: Systematic Review and Network Meta‐Analysis

Daniela Gorski iD, Raul Edison Luna Lazo iD, Dalton de Assis de Souza, Helena Hiemisch Lobo Borba iD, Roberto Pontarolo iD, Fernanda Stumpf Tonin iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025-09 · 45 (9) · 587-599

DOI: 10.1002/phar.70049 ↗

At a glance

Systematische Übersicht in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2025-08-07. Written by Daniela Gorski and 5 co-authors. Institution: Pharmaceutical Sciences Postgraduate Program, Health Sciences Sector, Universidade Federal do Paraná, Curitiba, Brazil. Major MEDLINE topics: Biological Products, Crohn Disease, Gastrointestinal Agents. Cited 3 times so far (Crossref); 60 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministry of Education of Brazil (CAPES), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

First‐line therapeutic approaches for Crohn's disease include immunosuppressants, aminosalicylates, and corticosteroids. However, more than one‐third of patients are resistant to these treatments and require second‐line therapies. Our goal was to synthesize the evidence on the efficacy and safety of biologics and small molecules for inducing remission in patients with moderate‐to‐severe Crohn's disease. A systematic review was conducted by searching for randomized controlled trials on the target population in PubMed, Scopus, and Web of Science (March 2025). Data synthesis for the outcomes of remission, health‐related quality of life (HRQoL), and safety was performed using network meta‐analyses and surface under the cumulative rating curve (SUCRA) analyses. The results were presented as risk ratios with 95% credible intervals. We included 55 trials ( n = 16,113 patients) evaluating 26 biological drugs across 83 doses and six small molecules across 15 doses. Similar results were obtained in the sensitivity analyses conducted across different measurement time points. Alongside infliximab 5 mg/kg (SUCRA 98.6%), 10 mg/kg (92%), and 20 mg/kg intravenous (91.8%), the recently approved drugs guselkumab 1200 mg (83.2%), 600 mg (89.2%), and 200 mg intravenous (90.1%), as well as mirikizumab 600 mg (91.5%) and 1000 mg intravenous (82.4%) presented higher probabilities of disease remission and were associated with increased HRQoL. Drugs such as certolizumab, andecaliximab, fontolizumab, abatacept, and etanercept ranked low for remission (SUCRA < 40%) and presented high probabilities of serious adverse events (over 60%). Small molecules presented an intermediate profile. Inhibitors of interleukin‐23 appear to be promising alternatives for the treatment of moderate‐to‐severe Crohn's disease. Given their safety profile, some anti‐TNF drugs should be avoided in practice. Trial Registration: PROSPERO: CRD42024519150

Subjects

MeSH terms (MEDLINE)

Biological ProductsCrohn DiseaseGastrointestinal AgentsAdultHumansQuality of LifeRandomized Controlled Trials as TopicRemission Induction

Author keywords

CINeMARCT comparisoninterleukin inhibitorsmonoclonal antibody

Substances

Biological ProductsGastrointestinal Agents

Authors and institutions

  • Pharmaceutical Sciences Postgraduate Program, Health Sciences Sector, Universidade Federal do Paraná, Curitiba, Brazil.
  • Department of Pharmacy, Universidade Federal do Paraná, Curitiba, Brazil.
  • Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Granada, Granada, Spain.

ORCID profiles: Daniela Gorski, Raul Edison Luna Lazo, Helena Hiemisch Lobo Borba, Roberto Pontarolo, Fernanda Stumpf Tonin

Funding

  • Ministry of Education of Brazil (CAPES)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Cite

APA

Gorski, D., Lazo, R. E. L., de Souza, D. A., Borba, H. H. L., Pontarolo, R., & Tonin, F. S. (2025). Biological Therapy and Small Molecules for Adults With Crohn's Disease: Systematic Review and Network Meta‐Analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 45(9), 587-599. https://doi.org/10.1002/phar.70049

Vancouver

Gorski D, Lazo REL, de Souza DA, Borba HHL, Pontarolo R, Tonin FS. Biological Therapy and Small Molecules for Adults With Crohn's Disease: Systematic Review and Network Meta‐Analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025;45(9):587-599. doi:10.1002/phar.70049

BibTeX
@article{Gorski2025,
  author = {Gorski, Daniela and Lazo, Raul Edison Luna and de Souza, Dalton de Assis and Borba, Helena Hiemisch Lobo and Pontarolo, Roberto and Tonin, Fernanda Stumpf},
  title = {Biological Therapy and Small Molecules for Adults With Crohn's Disease: Systematic Review and Network Meta‐Analysis},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  volume = {45},
  number = {9},
  pages = {587--599},
  doi = {10.1002/phar.70049}
}
Start for free →